Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The FORESEE Trial, Met Its Primary Endpoint Of Clinical Utility
Plus Therapeutics Has Acquired Assets For The Synergistic Leptomeningeal Metastases Diagnostic Platform, Financial Terms Not Disclosed; Topline Clinical Trial Data On The FORESEE Trial, Met Its Primary Endpoint Of Clinical Utility
Plus Therapeutics已收购协同轻脑膜转移诊断平台的资产，财务条款未披露；FORESEE试验的主要临床试验数据达到了临床效用的主要终点
CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rhenium (Re186) obisbemeda
CNSide 可以显著提高 LM 的诊断准确性和 Plus 的主要 LM 候选放射治疗药物铑 (Re186) obisbemeda 的市场规模
Company summarized topline data from the FORESEE clinical trial planned for complete presentation at the SNO/ASCO Meeting in August 2024
公司总结了计划在 2024 年 8 月的 SNO/ASCO 会议上完整展示的 FORESEE 临床试验的关键数据
Call replay & transcript available via the link below
电话重播和笔录可通过以下链接获得
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。